Immunohistochemistry in peritoneal mesothelioma a single-center experience of 244 cases Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Enzyme Activators
  • Protein Phosphatase 2
  • Proto-Oncogene Proteins p21(ras)

abstract

  • - The results support the experience that there is no definitive marker to rule out malignant mesothelioma, including PAX8, estrogen receptor, progesterone receptor, and p63 immunoreactivity. The high rate of immunoreactivity for mesothelin may have a role as a predictive marker for immune targeting. BAP1 loss of 55% in this cohort of peritoneal mesothelioma confirms published observations, and BAP1 retention is seen in a significant proportion of neoplastic cases.

publication date

  • February 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.5858/arpa.2017-0092-OA

PubMed ID

  • 29048219

Additional Document Info

start page

  • 236

end page

  • 242

volume

  • 142

number

  • 2